ST-segment Elevation Myocardial Infarction
Conditions
Keywords
melatonin, STEMI, No-reflow
Brief summary
ST-segment elevation myocardial infarction (STEMI) is an acute manifestation of coronary heart disease, remaining a frequent cause of death. A better understanding of risk factors and pathogenic mechanisms underlying STEMI may help improve the prognosis and life quality of these patients. Melatonin is the chief indoleamine produced by the pineal gland, and a well-known antioxidant and free radical scavenger. Basic studies have showed that melatonin is associated with myocardial infarction and heart failure. However, no study has evaluated whether melatonin is associated with adverse clinical outcomes in STEMI patients.
Interventions
None listed
Sponsors
Chinese PLA General Hospital
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
a diagnosis of STEMI and needed PCI
Exclusion criteria
patients with cancer patients who used melatonin
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| a change in the prevalence of no-reflow | mediately after percutaneous coronary intervention (PCI) | Thrombolysis in myocardial infarction (TIMI) flow grade of \<3 with a myocardial blush grade of 0-1 was defined as angiographic no-reflow |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| in-hospital complications | up to 2 weeks after PCI | defined as acute heart failure, atrial fibrillation, chest pain or recurrence of myocardial infarction, complete atrioventricular block, cerebrovascular disease, ventricular fibrillation or ventricular tachycardia |
| in-hospital major adverse cardiac or cerebrovascular events | up to 2 weeks after PCI | the composite of death, nonfatal MI, or stroke |
Outcome results
None listed